Report Detail

Pharma & Healthcare Bacterial Vaginosis - Pipeline Review, H2 2019

  • RnM3784250
  • |
  • 26 September, 2019
  • |
  • Global
  • |
  • 66 Pages
  • |
  • Global Markets Direct
  • |
  • Pharma & Healthcare

Bacterial Vaginosis - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Vaginosis - Pipeline Review, H2 2019, provides an overview of the Bacterial Vaginosis (Infectious Disease) pipeline landscape.

Bacterial vaginosis (BV), also known as vaginal bacteriosis is a type of vaginal inflammation caused by overgrowth of bacteria present in vagina. Symptoms include vaginal itching; burning during urination and vaginal discharge may become watery and thin. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacterial Vaginosis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Bacterial Vaginosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Vaginosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Unknown stages are 1, 6, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Bacterial Vaginosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Bacterial Vaginosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bacterial Vaginosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bacterial Vaginosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Vaginosis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bacterial Vaginosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bacterial Vaginosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Bacterial Vaginosis - Overview

              Bacterial Vaginosis - Therapeutics Development

                Pipeline Overview

                  Pipeline by Companies

                    Pipeline by Universities/Institutes

                      Products under Development by Companies

                        Products under Development by Universities/Institutes

                          Bacterial Vaginosis - Therapeutics Assessment

                            Assessment by Target

                              Assessment by Mechanism of Action

                                Assessment by Route of Administration

                                  Assessment by Molecule Type

                                    Bacterial Vaginosis - Companies Involved in Therapeutics Development

                                      Dare Bioscience Inc

                                        Evofem Biosciences Inc

                                          Melinta Therapeutics Inc

                                            Next Science Ltd

                                              Osel Inc

                                                Pharmiva AB

                                                  Starpharma Holdings Ltd

                                                    TenNor Therapeutics Ltd

                                                      Bacterial Vaginosis - Drug Profiles

                                                        Amphora - Drug Profile

                                                          Product Description

                                                            Mechanism Of Action

                                                              R&D Progress

                                                                astodrimer - Drug Profile

                                                                  Product Description

                                                                    Mechanism Of Action

                                                                      R&D Progress

                                                                        Biologic for Bacterial Vaginosis - Drug Profile

                                                                          Product Description

                                                                            Mechanism Of Action

                                                                              R&D Progress

                                                                                clindamycin - Drug Profile

                                                                                  Product Description

                                                                                    Mechanism Of Action

                                                                                      R&D Progress

                                                                                        Drug for Bacterial Vaginosis - Drug Profile

                                                                                          Product Description

                                                                                            Mechanism Of Action

                                                                                              R&D Progress

                                                                                                LACTIN-V - Drug Profile

                                                                                                  Product Description

                                                                                                    Mechanism Of Action

                                                                                                      R&D Progress

                                                                                                        metronidazole - Drug Profile

                                                                                                          Product Description

                                                                                                            Mechanism Of Action

                                                                                                              R&D Progress

                                                                                                                P-001 - Drug Profile

                                                                                                                  Product Description

                                                                                                                    Mechanism Of Action

                                                                                                                      R&D Progress

                                                                                                                        radezolid - Drug Profile

                                                                                                                          Product Description

                                                                                                                            Mechanism Of Action

                                                                                                                              R&D Progress

                                                                                                                                Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile

                                                                                                                                  Product Description

                                                                                                                                    Mechanism Of Action

                                                                                                                                      R&D Progress

                                                                                                                                        subtilosin - Drug Profile

                                                                                                                                          Product Description

                                                                                                                                            Mechanism Of Action

                                                                                                                                              R&D Progress

                                                                                                                                                TNP-2198 - Drug Profile

                                                                                                                                                  Product Description

                                                                                                                                                    Mechanism Of Action

                                                                                                                                                      R&D Progress

                                                                                                                                                        TOL-463 - Drug Profile

                                                                                                                                                          Product Description

                                                                                                                                                            Mechanism Of Action

                                                                                                                                                              R&D Progress

                                                                                                                                                                Bacterial Vaginosis - Dormant Projects

                                                                                                                                                                  Bacterial Vaginosis - Discontinued Products

                                                                                                                                                                    Bacterial Vaginosis - Product Development Milestones

                                                                                                                                                                      Featured News & Press Releases

                                                                                                                                                                        Aug 15, 2019: First Asian regulatory approvals received for VivaGel BV

                                                                                                                                                                          Aug 12, 2019: Daré Bioscience receives QIDP Designation from the FDA for DARE-BV1 for the treatment of Bacterial Vaginosis

                                                                                                                                                                            Aug 08, 2019: Dare announces presentation of positive clinical findings for vaginal administration of novel formulation of clindamycin phosphate for the treatment of bacterial vaginosis at the 2019 Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology

                                                                                                                                                                              Apr 16, 2019: First VivaGel BV launch globally in Australia by Aspen

                                                                                                                                                                                Mar 18, 2019: Dare Bioscience to present update on Bacterial Vaginosis program DARE-BV1 at 31st Annual ROTH Conference

                                                                                                                                                                                  Sep 21, 2018: New Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Amphora and its Role as a Multipurpose Vaginal pH Regulator (MVP-R) to be Presented at the 2018 American Society For Reproductive Medicine Annual Congress

                                                                                                                                                                                    Jul 09, 2018: VivaGel BV NDA advances to next stage of FDA review

                                                                                                                                                                                      Apr 30, 2018: Starpharma completes US New Drug Application for VivaGel BV

                                                                                                                                                                                        Jan 18, 2018: Melinta Therapeutics Announces Initiation of Program for Radezolid in Patients with Bacterial Vaginosis

                                                                                                                                                                                          Jan 17, 2018: Osel’s LACTIN-V Enters Clinical Study to Improve the Success Rate of IVF in Women With Imbalanced Vaginal Microbiomes

                                                                                                                                                                                            Nov 21, 2017: Starpharma: NDA submission for VivaGel BV in the US

                                                                                                                                                                                              Oct 25, 2017: VivaGel BV granted marketing approval in Australia

                                                                                                                                                                                                Aug 07, 2017: Successful VivaGel Phase 3 results and NDA planned for rBV

                                                                                                                                                                                                  Jul 27, 2017: Evofem Biosciences Announces First Patient Enrolled in a Phase 3 Clinical Trial of AMPHORA for Prevention of Pregnancy

                                                                                                                                                                                                    Jul 04, 2017: VivaGel BV phase 3 results timing and commercialisation

                                                                                                                                                                                                      Appendix

                                                                                                                                                                                                        Methodology

                                                                                                                                                                                                          Coverage

                                                                                                                                                                                                            Secondary Research

                                                                                                                                                                                                              Primary Research

                                                                                                                                                                                                                Expert Panel Validation

                                                                                                                                                                                                                  Contact Us

                                                                                                                                                                                                                    Disclaimer

                                                                                                                                                                                                                    Summary:
                                                                                                                                                                                                                    Get latest Market Research Reports on Bacterial Vaginosis. Industry analysis & Market Report on Bacterial Vaginosis is a syndicated market report, published as Bacterial Vaginosis - Pipeline Review, H2 2019. It is complete Research Study and Industry Analysis of Bacterial Vaginosis market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                                                                                                                                    Last updated on

                                                                                                                                                                                                                    REPORT YOU MIGHT BE INTERESTED

                                                                                                                                                                                                                    Purchase this Report

                                                                                                                                                                                                                    $2,000.00
                                                                                                                                                                                                                    $4,000.00
                                                                                                                                                                                                                    $6,000.00
                                                                                                                                                                                                                    1,606.00
                                                                                                                                                                                                                    3,212.00
                                                                                                                                                                                                                    4,818.00
                                                                                                                                                                                                                    1,878.00
                                                                                                                                                                                                                    3,756.00
                                                                                                                                                                                                                    5,634.00
                                                                                                                                                                                                                    309,080.00
                                                                                                                                                                                                                    618,160.00
                                                                                                                                                                                                                    927,240.00
                                                                                                                                                                                                                    167,160.00
                                                                                                                                                                                                                    334,320.00
                                                                                                                                                                                                                    501,480.00
                                                                                                                                                                                                                    Credit card Logo

                                                                                                                                                                                                                    Related Reports


                                                                                                                                                                                                                    Reason to Buy

                                                                                                                                                                                                                    Request for Sample of this report